Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;74(12):2312-2319.
doi: 10.1111/all.13875. Epub 2019 Jul 15.

EUFOREA consensus on biologics for CRSwNP with or without asthma

Wytske J Fokkens  1   2 , Valerie Lund  3 , Claus Bachert  2   4   5 , Joaquim Mullol  6 , Leif Bjermer  7 , Jean Bousquet  2   8 , Giorgio W Canonica  9   10 , Lauren Deneyer  2 , Martin Desrosiers  11 , Zuzana Diamant  7   12   13 , Joseph Han  14 , Enrico Heffler  9   10 , Claire Hopkins  15 , Roger Jankowski  16 , Guy Joos  17 , Andrew Knill  18 , Jivianne Lee  19 , Stella E Lee  20 , Gert Mariën  2 , Benoit Pugin  2   21 , Brent Senior  22 , Sven F Seys  2   21 , Peter W Hellings  1   2   21   23
Affiliations
Review

EUFOREA consensus on biologics for CRSwNP with or without asthma

Wytske J Fokkens et al. Allergy. 2019 Dec.

Abstract

Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4Rα, anti-IL5, and anti-IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.

Keywords: asthma; biologics; chronic rhinosinusitis; nasal polyps; type 2 inflammation.

PubMed Disclaimer

Conflict of interest statement

Dr. Diamant reports personal fees from AstraZeneca, personal fees from Sanofi‐Genzyme, during the conduct of the study; personal fees from Aquilon, personal fees from ALK, personal fees from Boehringer Ingelheim, personal fees from Gilead, personal fees from Hal Allergy, personal fees from MSD, outside the submitted work; and Apart from my academic affiliations I work at a phase I/II unit performing clinical studies for different biotech and pharma companies. Dr. Bachert reports personal fees from Sanofi, personal fees from GSK, personal fees from Novartis, personal fees from Astra‐Zeneca, during the conduct of the study. Dr. Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, outside the submitted work. Dr Han reports to be consultant for Sanofi/Genzyme Regeneron and Astra‐Zeneca. Dr. Hellings reports grants and personal fees from Mylan, during the conduct of the study; personal fees from Sanofi, personal fees from Allergopharma, personal fees from Stallergenes, outside the submitted work. Dr. Hopkins reports personal fees from Advisory Board Participation ‐ Sanofi, personal fees from Advisory Board Participation – Glaxo Smith Kline, personal fees from Advisory Board Participation ‐ Optinose, personal fees from Advisory Board Participation – Smith and Nephew, outside the submitted work. Dr. J. Lee reports grants from Astra‐Zeneca, personal fees from Regeneron Healthcare Solutions, during the conduct of the study. Dr. Jankowski reports personal fees from sanofi regeneron, outside the submitted work. Dr. Joos reports grants and personal fees from AstraZeneca, personal fees from Eureca vzw, grants from Chiesi, grants and personal fees from GlaxoSmithKline, personal fees from Teva, outside the submitted work; all payments were done to his employer. Dr. S. Lee reports grants from Sanofi Regeneron, grants from Allakos Inc, grants from Astra Zeneca, other from Novartis, other from Sanofi Regeneron, outside the submitted work. Dr. Lund reports non‐financial support from GSK, grants from GSK, during the conduct of the study; personal fees from Abbott, personal fees from Kyorin, personal fees from MIMS, personal fees from MSD, personal fees from Elsevier Editor, outside the submitted work. Dr. Mullol reports personal fees and other from SANOFI‐GENZYME & REGENERON, NOVARTIS, and ALLAKOS; grants and personal fees from MYLAN Pharma and URIACH Group; and personal fees from ALK‐Abelló A/S, Menarini, and UCB, outside the submitted work. Dr. Heffler reports grants from AstraZeneca, grants from GSK, grants from Sanofi‐Genzyme, grants from Novartis, grants from Nestlè Purina, grants from Circassia, outside the submitted work. Dr Fokkens reports grants from Sanofi, grants from GSK, grants from Novartis, during the conduct of the study. Dr. Bjermer, Dr. Deneyer, Dr. Desrosiers, Dr. Knill, Dr. Mariën, Dr. Seys, Dr. Senior, Dr. Pugin hava nothing to disclose.

Figures

Figure 1
Figure 1
Indications for biological treatment in patients with CRSwNP: proposal of the multidisciplinary EUFOREA Expert Board Meeting
Figure 2
Figure 2
Response criteria for biological treatment in patients with CRSwNP: proposal of the multidisciplinary EUFOREA Expert Board Meeting
See this image and copyright information in PMC

References

    1. Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe–an underestimated disease. A GA2LEN study. Allergy. 2011;66(9):1216‐1223. - PubMed
    1. Hirsch AG, Stewart WF, Sundaresan AS, et al. Nasal and sinus symptoms and chronic rhinosinusitis in a population‐based sample. Allergy. 2017;72(2):274‐281. - PMC - PubMed
    1. Ostovar A, Fokkens WJ, Vahdat K, Raeisi A, Mallahzadeh A, Farrokhi S. Epidemiology of chronic rhinosinusitis in Bushehr, southwestern region of Iran: a GA2LEN study. Rhinology. 2018;57(1):43‐48. - PubMed
    1. Shi JB, Fu QL, Zhang H, et al. Epidemiology of chronic rhinosinusitis: results from a cross‐sectional survey in seven Chinese cities. Allergy. 2015;70(5):533‐539. - PMC - PubMed
    1. Fokkens WJ, Lund VJ, Mullol J et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2012;23:3 p preceding table of contents, 1‐298. - PubMed

Publication types

Substances